Luxturna: latest news - GoINPHARMA
Saturday, 15 December 2018 - 5:38

Luxturna

Novartis to pay $170m for Spark Therapeutics’ gene therapy

Novartis’ new CEO Vas Narasimhan appears to be fulfilling the promises made when he was appointed, as he announced he was determined to invest on gene therapies. Novartis announced yesterday night that it has acquired the commercialization rights outside the…

Monthly review: October

October has brought interesting news in the pharmaceutical industry. Among the most significant news published in GoINPHARMA, the growing rumors on Amazon about to debut in healthcare surely rank first. The US-based distribution giant is likely to start launching drugs…